SAINT LAURENT, QUEBEC AND TORONTO, ONTARIO--(Marketwire - March 4, 2010) - IntelGenx Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) and Cannasat Therapeutics Inc. (TSX VENTURE:CTH) announced today that they have entered into a Letter of Intent (“LOI”). Under the terms of the LOI, IntelGenx would acquire a fifty percent ownership stake from Cannasat and an exclusive worldwide license to develop and commercialize Relivar, a novel formulation of dronabinol, utilizing IntelGenx’s proprietary mucoadhesive AdVersa technology, for the treatment of various diseases including neuropathic pain.
